Back to top

Image: Bigstock

Emergent BioSolutions, Inc.

Read MoreHide Full Article

Emergent reported better than expected earnings in the first quarter of 2017. However, revenue missed estimates in the quarter. BioThrax is the key product at the company’s Biodefense segment and the U.S. government is the primary purchaser of its Biodefense products. Hence, the company’s sole dependence on BioThrax for its revenue is concerning. Moreover, Emergent faces competition from a number of companies with Biodefense products, which could adversely affect the company’s operating results. Shares of the company have underperformed the broader industry so far this year. However, the company’s follow-on contract with the CDC for BioThrax and deals with the BARDA for BioThrax and NuThrax (the next-generation anthrax vaccine candidate) bodes well for growth. NuThrax’s approval will be a huge boost for the company.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Emergent Biosolutions Inc. (EBS) - free report >>

Published in